Mitochondrial E3 Ubiquitin Ligase Parkin: Relationships with Other Causal Proteins in Familial Parkinson's Disease and Its Substrate-Involved Mouse Experimental Models.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 Feb 2020
Historique:
received: 22 01 2020
revised: 07 02 2020
accepted: 09 02 2020
entrez: 15 2 2020
pubmed: 15 2 2020
medline: 21 11 2020
Statut: epublish

Résumé

Parkinson's disease (PD) is a common neurodegenerative disorder. Recent identification of genes linked to familial forms of PD has revealed that post-translational modifications, such as phosphorylation and ubiquitination of proteins, are key factors in disease pathogenesis. In PD, E3 ubiquitin ligase Parkin and the serine/threonine-protein kinase PTEN-induced kinase 1 (PINK1) mediate the mitophagy pathway for mitochondrial quality control via phosphorylation and ubiquitination of their substrates. In this review, we first focus on well-characterized PINK1 phosphorylation motifs. Second, we describe our findings concerning relationships between Parkin and HtrA2/Omi, a protein involved in familial PD. Third, we describe our findings regarding inhibitory PAS (Per/Arnt/Sim) domain protein (IPAS), a member of PINK1 and Parkin substrates, involved in neurodegeneration during PD. IPAS is a dual-function protein involved in transcriptional repression of hypoxic responses and the pro-apoptotic activities.

Identifiants

pubmed: 32054064
pii: ijms21041202
doi: 10.3390/ijms21041202
pmc: PMC7072767
pii:
doi:

Substances chimiques

Ubiquitin-Protein Ligases EC 2.3.2.27
parkin protein EC 2.3.2.27
Protein Kinases EC 2.7.-
PTEN-induced putative kinase EC 2.7.11.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

FEBS J. 2017 Dec;284(23):4115-4127
pubmed: 29054108
Nat Commun. 2012;3:1016
pubmed: 22910362
J Biochem. 2016 Apr;159(4):379-85
pubmed: 26839319
J Biol Chem. 2002 Jan 4;277(1):439-44
pubmed: 11602612
J Biol Chem. 2009 Jul 10;284(28):19077-89
pubmed: 19433582
Neuroscience. 2012 Jun 1;211:51-76
pubmed: 22108613
Sci Rep. 2012;2:1002
pubmed: 23256036
Mol Cell. 2019 Apr 18;74(2):320-329.e6
pubmed: 30853402
J Biochem. 2011 Sep;150(3):311-8
pubmed: 21558328
J Parkinsons Dis. 2017;7(1):13-29
pubmed: 27911343
J Neural Transm (Vienna). 2017 Sep;124(9):1037-1054
pubmed: 28620835
Nat Protoc. 2007;2(1):141-51
pubmed: 17401348
J Pharmacol Sci. 2014;124(3):287-93
pubmed: 24553453
Exp Neurobiol. 2015 Jun;24(2):103-16
pubmed: 26113789
J Neurochem. 2008 Jun;105(5):2039-52
pubmed: 18298661
J Cell Biol. 2010 Apr 19;189(2):211-21
pubmed: 20404107
PLoS Biol. 2007 Jul;5(7):e172
pubmed: 17579517
J Biochem. 2017 Mar 1;161(3):291-296
pubmed: 28003430
EMBO J. 2012 Jun 26;31(14):3038-62
pubmed: 22735187
Cell. 2011 Nov 11;147(4):893-906
pubmed: 22078885
Mol Ther. 2006 Nov;14(5):716-23
pubmed: 16914382
Nature. 2014 Jun 5;510(7503):162-6
pubmed: 24784582
Cell Death Differ. 2012 Feb;19(2):257-66
pubmed: 21701498
J Biol Chem. 2000 Jan 28;275(4):2581-8
pubmed: 10644717
Proc Natl Acad Sci U S A. 1985 Apr;82(7):2173-7
pubmed: 3872460
Cell Death Discov. 2015 Aug 17;1:15015
pubmed: 27551449
Biochem Biophys Res Commun. 2010 Nov 26;402(4):676-9
pubmed: 20971077
Eur J Pharmacol. 1990 May 3;180(1):59-67
pubmed: 2365003
Mol Cell Proteomics. 2006 Apr;5(4):749-57
pubmed: 16340016
Cell Death Dis. 2015 Sep 17;6:e1886
pubmed: 26379191
Cell Rep. 2017 Jan 24;18(4):918-932
pubmed: 28122242
J Biochem. 2013 Dec;154(6):561-7
pubmed: 24092767
Mol Cell. 2001 Sep;8(3):613-21
pubmed: 11583623
Hum Mol Genet. 2011 Mar 1;20(5):867-79
pubmed: 21138942
Biochem Biophys Res Commun. 2005 Dec 9;338(1):610-6
pubmed: 16154531
Lancet Neurol. 2015 Mar;14(3):274-82
pubmed: 25662902
Nature. 2003 Oct 16;425(6959):721-7
pubmed: 14534547
Exp Neurol. 2002 May;175(1):87-97
pubmed: 12009762
Exp Neurol. 2007 Oct;207(2):289-301
pubmed: 17678648
Cell. 2001 Jun 29;105(7):891-902
pubmed: 11439185
Int J Mol Sci. 2019 Feb 20;20(4):
pubmed: 30791515
Biochem Biophys Res Commun. 2010 Mar 5;393(2):264-7
pubmed: 20123086
Cell Death Differ. 2011 Nov;18(11):1711-25
pubmed: 21546903
Mol Brain. 2019 Nov 29;12(1):100
pubmed: 31783880
Hum Mutat. 2012 Oct;33(10):1408-22
pubmed: 22644621
Elife. 2018 Jan 23;7:
pubmed: 29360040
ACS Chem Biol. 2017 Oct 20;12(10):2546-2551
pubmed: 28925688
Toxicology. 1988 Apr;49(1):17-23
pubmed: 3287690
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):12022-7
pubmed: 18687899
EMBO Rep. 2019 Dec 5;20(12):e47728
pubmed: 31602805
J Neurosci. 2008 Nov 19;28(47):12500-9
pubmed: 19020042
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10810-4
pubmed: 15252205
Open Biol. 2012 May;2(5):120080
pubmed: 22724072
Hum Mol Genet. 2015 May 1;24(9):2528-38
pubmed: 25612572
Hum Mol Genet. 2014 Oct 1;23(19):5227-42
pubmed: 24852371
FEBS Lett. 2018 Aug;592(16):2769-2775
pubmed: 30047986
Hum Mol Genet. 2013 Apr 15;22(8):1558-73
pubmed: 23307929
Nature. 2014 Jun 19;510(7505):370-5
pubmed: 24896179
Science. 2013 Apr 26;340(6131):471-5
pubmed: 23620051
FEBS J. 2016 Mar;283(6):993-1003
pubmed: 26507580
Nat Commun. 2017 Jun 07;8:15500
pubmed: 28589937
Cold Spring Harb Perspect Med. 2012 Jan;2(1):a008888
pubmed: 22315721
Neuron. 2002 Dec 19;36(6):1007-19
pubmed: 12495618
Science. 1983 Feb 25;219(4587):979-80
pubmed: 6823561
PLoS Genet. 2014 Dec 04;10(12):e1004861
pubmed: 25474007
J Biol Chem. 2007 May 11;282(19):14073-82
pubmed: 17355974
Genomics. 1993 Jun;16(3):669-77
pubmed: 8325640
Mol Cell. 2018 Mar 1;69(5):744-756.e6
pubmed: 29456190
Cell Death Differ. 2010 Jul;17(7):1115-25
pubmed: 20094060
Nature. 2001 Nov 29;414(6863):550-4
pubmed: 11734856
Hum Mol Genet. 2019 Dec 1;28(23):3895-3911
pubmed: 31600778
Neurosci Res. 2007 Dec;59(4):413-25
pubmed: 17889953
Nat Cell Biol. 2007 Nov;9(11):1243-52
pubmed: 17906618
Neurosci Lett. 2006 Jun 19;401(1-2):130-5
pubmed: 16554120

Auteurs

Satoru Torii (S)

Department of Pathological Cell Biology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.

Shuya Kasai (S)

Department of Stress Response Science, Center for Advanced Medical Research, Graduate School of Medicine, Hirosaki University, 5 Zaifu-cho, Hirosaki, Aomori 036-8562, Japan.

Tatsushi Yoshida (T)

Department of Biochemistry and Molecular Biology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.

Ken-Ichi Yasumoto (KI)

Department of Molecular and Chemical Life Sciences, Graduate School of Life Sciences, Tohoku University, Sendai 980-8578, Japan.

Shigeomi Shimizu (S)

Department of Pathological Cell Biology, Medical Research Institute, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH